First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
Crossref DOI link: https://doi.org/10.1007/s11523-015-0381-x
Published Online: 2015-08-27
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dienstmann, Rodrigo
Lassen, Ulrik
Cebon, Jonathan
Desai, Jayesh
Brown, Michael P.
Evers, Stefan
Su, Fei
Zhang, Weijiang
Boisserie, Frederic
Lestini, Brian
Schostack, Kathleen
Meresse, Valerie
Tabernero, Josep
Text and Data Mining valid from 2015-08-27